






DPW

				TRANSMITTAL LETTER (General - Patent Pending)		Docket No. 01084/2/US													
In Re Application Of: Graneto et al.																			
Application No. 10/667,622		Filing Date September 22, 2003		Examiner Stockton		Customer No. 26648		Group Art Unit 1614		Confirmation No. 1183									
Title: CELECOXIB PRODRUG																			
<u>COMMISSIONER FOR PATENTS:</u>																			
Transmitted herewith is: Form 1449; Second Supplemental Information Disclosure Statement; 1 cited reference; Itemized Postcard.																			
in the above identified application.																			
<input checked="" type="checkbox"/> No additional fee is required. <input type="checkbox"/> A check in the amount of _____ is attached. <input checked="" type="checkbox"/> The Director is hereby authorized to charge and credit Deposit Account No. 19-1025 as described below. <input type="checkbox"/> Charge the amount of _____ <input type="checkbox"/> Credit any overpayment. <input checked="" type="checkbox"/> Charge any additional fee required. <input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.																			
 _____ Signature						Dated: May 2, 2005													
Patricia K. Fitzsimmons, Reg. No. 52,894 Pharmacia Corporation of Pfizer Inc. P.O. Box 1027 Chesterfield, Missouri 63006 314.274.1490						<table border="1"><tr><td colspan="2">I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on May 2, 2005 (Date)</td></tr><tr><td colspan="2"> Signature of Person Mailing Correspondence</td></tr><tr><td colspan="2">Linda K. Cooper</td></tr><tr><td colspan="2">Typed or Printed Name of Person Mailing Correspondence</td></tr></table>						I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on May 2, 2005 (Date)		 Signature of Person Mailing Correspondence		Linda K. Cooper		Typed or Printed Name of Person Mailing Correspondence	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on May 2, 2005 (Date)																			
 Signature of Person Mailing Correspondence																			
Linda K. Cooper																			
Typed or Printed Name of Person Mailing Correspondence																			
cc:																			



Sheet 1 of 1

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.: 01084/2/US	APPLICATION NO.: 10/667,622
	INVENTOR: Graneto et al.	
	Filed: 09/22/2003	Group: 1614

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS


Examiner Initial	Document Number							Translation	
								Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial	
	Pal, Manojit et al., <i>Journal of Medical Chemistry</i> ; <u>Synthesis and Cyclooxygenase-2 Inhibiting Property of 1,5-Diarylpyrazoles with Substituted Benzenesulfonamide Moiety as Pharmacophore: Preparation of Sodium Salt for Injectable Formulation</u> ; 46, 3975-3984.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

(Form PTO-1449)



Case 01084/2/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Graneto et al.

SERIAL NO.: 10/667,622

FILED: 22 September 2003

TITLE: CELECOXIB PRODRUG

GROUP ART UNIT: 1614

EXAMINER: Stockton

DATE: May 2, 2005

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97-1.98

Commissioner of Patents
Box 1450
Alexandria, VA 22313

Sir:

This Supplemental Information Disclosure Statement is filed pursuant to 37 CFR 1.97-1.98 and MPEP §609. The present Information Disclosure Statement supplements the Information Disclosure Statements previously filed. Any fee required by 37 CFR 1.97-1.98 should be charged to Deposit Account No. 19-1025.

Respectfully submitted,

Patricia K. Fitzsimmons
Attorney for Applicants
Registration No. 52,894
(314) 274-1490 (St. Louis)

Pharmacia Corporation
Global Patent Department
Post Office Box 1027
St. Louis, MO 63006